Current and emerging sublingual immunotherapies for dust mite allergy
Expert Opinion on Biological Therapy · 02.11.2026 · 26 (11) · 1259-1272
DOI: 10.1080/14712598.2026.2751908 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Biological Therapy, online erschienen am 23.10.2026. Verfasst von Wen-Cheng Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Sublingual Immunotherapy, Dust Mite Allergy, Asthma, Rhinitis, Allergic. Die Arbeit nennt 86 Literaturangaben. Gefördert von: Jiangsu Province Capability Improvement Project through Science, Technology and Education.
Abstract (Originalsprache)
INTRODUCTION: House dust mites (HDMs) are the most prevalent inhalant allergens globally, inducing a spectrum of allergic diseases including allergic rhinitis (AR) and asthma, which substantially impair patients' quality of life. Sublingual immunotherapy (SLIT) is recognized as a promising disease-modifying intervention for HDM-related allergic disorders. AREAS COVERED: This paper presents a narrative review of up-to-date clinical evidence regarding SLIT for HDM allergy (HDM-SLIT), covering its therapeutic efficacy, patient selection criteria, dose optimization strategies, safety profiles, underlying immunological mechanisms, and unresolved clinical challenges. EXPERT OPINION: HDM-SLIT has been established as a disease-modifying therapy for HDM-induced AR and asthma, with supporting evidence demonstrating its clinical efficacy, favorable safety profile, and long-lasting tolerability. Future developments in precision allergology, including multiomics-derived biomarkers and digital health applications, show considerable potential to guide clinical decision-making. However, the translation of these advances into routine clinical practice remains limited by gaps in insurance reimbursement, suboptimal patient adherence, inconsistent regulatory standards across regions, insufficient product standardization, and inequitable access to healthcare resources.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
- Department of Allergology & Clinical Allergy Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
ORCID-Profile: Lei Cheng
Förderung
- Jiangsu Province Capability Improvement Project through Science, Technology and Education
Zitieren
APA
Zhou, W. C., Li, S., & Cheng, L. (2026). Current and emerging sublingual immunotherapies for dust mite allergy. Expert Opinion on Biological Therapy, 26(11), 1259-1272. https://doi.org/10.1080/14712598.2026.2751908
Vancouver
Zhou WC, Li S, Cheng L. Current and emerging sublingual immunotherapies for dust mite allergy. Expert Opinion on Biological Therapy. 2026;26(11):1259-1272. doi:10.1080/14712598.2026.2751908
BibTeX
@article{Zhou2026,
author = {Zhou, Wen-Cheng and Li, Song and Cheng, Lei},
title = {Current and emerging sublingual immunotherapies for dust mite allergy},
journal = {Expert Opinion on Biological Therapy},
year = {2026},
volume = {26},
number = {11},
pages = {1259--1272},
doi = {10.1080/14712598.2026.2751908}
}
EUVIMED